Arrhythmogenic Cardiomyopathy research hub

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

This study is testing a new drug called Tideglusib for a heart condition called Arrhythmogenic Cardiomyopathy (ACM). It aims to see if the drug can help improve the condition by targeting specific pathways in the heart. The study is in its early stages.